What is the Purpose of this Study?
The purpose of this study is to assess the real-world use and outcomes of patients with non-muscle invasive bladder cancer (NMIBC) who are being treated with INLEXZO (previously known as TAR-200) in real-world clinical practice settings. NMIBC is a type of bladder cancer found in the tissue that lines the inside surface of the bladder. Adults with a confirmed diagnosis of NMIBC may join the study if they started their first dose of INLEXZO or will begin their first dose within 6 weeks before their first or baseline study visit. The study does not require any specific testing or additional visits other than standard-of-care. Researchers will collect information about how well the treatment works and any side effects or safety concerns patients may have.
Eligibility
Not Available
Where can I participate?
Beverly
What is the full name of this clinical trial?
A multicenter, prospective, longitudinal study to assess real-world use and outcomes after the launch of TAR-200 for NMIBC in the US